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Abstract

Background — Design of efficient nonviral gene delivery systems is limited as a result of the rudimentary understanding of the specific molecules and processes that facilitate DNA transfer.
Methods — Lipoplexes formed with Lipofectamine 2000 (LF2000) and plasmid-encoding green fluorescent
protein (GFP) were delivered to the HEK 293T cell line. After treating cells with lipoplexes, HG-U133 Affymetrix microarrays were used to identify endogenous genes differentially expressed between treated
and untreated cells (2 h exposure) or between flow-separated transfected cells (GFP+) and treated, untransfected cells (GFP–) at 8, 16 and 24 h after lipoplex treatment. Cell priming studies were conducted
using pharmacologic agents to alter endogenous levels of the identified differentially expressed genes
to determine effect on transfection levels.
Results — Relative to untreated cells 2 h after lipoplex treatment, only downregulated genes were identified ≥ 30-fold: ALMS1, ITGB1, FCGR3A, DOCK10 and ZDDHC13. Subsequently, relative to GFP– cells,
the GFP+ cell population showed at least a five-fold upregulation of RAP1A and PACSIN3 (8 h) or HSPA6
and RAP1A (16 and 24 h). Pharmacologic studies altering endogenous levels for ALMS1, FCGR3A, and
DOCK10 (involved in filopodia protrusions), ITGB1 (integrin signaling), ZDDHC13 (membrane trafficking) and PACSIN3 (proteolytic shedding of membrane receptors) were able to increase or decrease
transgene production.
Conclusions — RAP1A, PACSIN3 and HSPA6 may help lipoplex-treated cells overcome a transcriptional
shutdown due to treatment with lipoplexes and provide new targets for investigating molecular mechanisms of transfection or for enhancing transfection through cell priming or engineering of the nonviral gene delivery system.
Keywords: ALMS1, FCGR3A, GFP, HEK 293T, ITGB1, microarray analysis, nonviral gene delivery, temporal gene expression profile

Introduction

applications in functional genomics [1], tissue engineering
[2], medical devices [3] and gene therapy [4, 5]. Viruses
and the profuse knowledge about the molecular mediators of viral infection [6] have been exploited to develop

DNA delivery provides a mechanism to directly alter endogenous gene expression and cellular behavior with
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very efficient viral gene delivery systems [7]. However, oncogenicity, immunogenicity, and the lack of repeated dosing
capability [8–11] of viruses have spurred research towards
enhancing the efficacy of nonviral DNA carriers. Nonviral
carriers such as cationic lipids (i.e. lipoplexes) [12–20] and
polymers (i.e. polyplexes) [21] do not have the problems
associated with viruses but suffer from low transfection.
However, an incomplete understanding of the molecules
and mechanisms that facilitate successful nonviral transfection precludes the efficient design of more efficient nonviral systems [19, 22–24].
Towards a better understanding of nonviral transfection,
transcriptome profiling has been used to identify the cellular and tissue response after treatment with nonviral gene
carriers by comparing treated samples with untreated samples [23, 25–29]. For example, a previous study used microarrays to identify the in vivo cellular response to treatment
of lipoplexes and found type I interferon to be upregulated in the spleen after treatment of polyethylene glycol-modified lipoplexes as a result of delayed endosomal
escape. That study provided a molecular framework to redesign the DNA carrier for improved safety of the lipoplex, informed through comparison of the gene expression
profiles of treated tissue to untreated tissue [7]. However,
that work was limited in that molecules facilitating transfection were not identified (i.e. no comparison of gene profiles from treated and transfected cells to treated but untransfected cells was made) to provide a molecular basis
to redesign the DNA carrier for improved transfection efficiency. Another study used microarrays to highlight the
time- and vector-dependence of the gene expression profile
of cells treated in vitro with lipoplexes, which showed different types of endogenous genes being over- and underexpressed at 8 h (stress-inducible, immune response, antiviral, cellular growth and division), 24h (cellular growth and
division, G protein-coupled receptors, heat shock proteins,
transcription/translation effectors, proteasome, senescence
and cytoskeletal) and 48 h (cellular growth and division,
transcription/translation effectors, Golgi-endoplasmic reticulum trafficking, heat shock proteins, DNA repair, cytoskeletal, and motility) [30] after DNA delivery, although, again,
in that work, transfected cells were not studied in isolation
and therefore the data provide information about cellular
response to treatment with lipoplexes but not about mechanisms that facilitate transfection. Gene expression profiling
has also been useful in assessing specific genes expressed
by epithelial cells in vitro to cope with treatment-induced
cytotoxicity and apoptosis, highlighting genes such as interleukin-9 receptor (IL-9R), heat shock protein 70 (HSP70) and
met proto-oncogene precursor (cMET) upregulated in cells
in lipoplex transfection [26]. Together, these previous studies show the usefulness of microarray analysis to identify
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genes and pathways elicited after treatment of cells or tissues with nonviral gene delivery systems and that the gene
expression profile can vary drastically at various time points
after treatment with lipoplexes. However, a substantial gap
in knowledge remains about molecules and pathways used
by cells to overcome the different barriers that occur over
time during DNA transfer [21, 31–43].
To identify mechanisms that facilitate transfection (i.e.
successful delivery of the transgene), a lipoplex-treated
population of cells can be separated into two subpopulations (transfected and untransfected) and, subsequently,
their transcriptome can be profiled using microarray analysis. When transfected and untransfected gene expression
profiles are compared, the identified differentially expressed
genes provide insight into molecules and mechanisms that
facilitate transfection [44, 45]. For example, in our previously
published study, we showed RAP1A and HSPA6 endogenous
genes to be overexpressed in transfected human embryonic epithelial kidney (HEK 293T) cells 24 h after delivery of
the GFP transgene using lipoplexes [45] or polyplexes [44],
compared to treated but untransfected cells. Subsequently,
priming cells for transfection by altering RAP1A or HSPA6
endogenous levels prior to polyplex or lipoplex treatment,
respectively, resulted in an up to 2.5-fold increase in transfection [44, 45]. Those studies demonstrated that transfection can be improved by targeting specific molecules that
are over- or under-expressed in transfected cells compared
to untransfected cells. Although targeting a single barrier
or step in DNA transfer often leads to improved transfection [46], it is unlikely that consideration of a single endogenous gene in DNA carrier design will lead to a therapeutically relevant transfection system. Instead, multi-faceted
approaches generally lead to improved transfection [47], although the genes and pathways implicated at other, earlier
stages of transfection (e.g. internalization, endosomal escape, nuclear localization, nuclear entry) [21, 31–43] remain
unidentified and prevent the design of efficient gene delivery systems. Because lipid and polymer DNA carriers have
shown promising in vitro and in vivo transfection [47], the
aim of the present study is to identify genes and pathways
implicated at these earlier stages for lipid vectors, whereas
our other work focuses on polymer vectors [48].
The objective of the present study was to identify endogenous genes differentially expressed at 2, 8, 16 and
24 h after delivery of the GFP transgene to HEK 293T cells
using a cationic lipid vector (Lipofectamine 2000; LF2000).
Relative to untreated cells, transcriptome profiling of HEK
293T cells at 2 h post-delivery of lipoplexes was used to
identify those endogenous genes that may act in response
to treatment stress such as toxicity induced by the complex [22] or inherent intracellular defenses against foreign
nucleic acids [49]. Relative to GFP– cells, transcriptome
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profiling was used to identify those endogenous genes
used by transfected cells (GFP+) that may aid in overcoming cellular barriers known to occur during DNA transfer
[21, 31–43] at 8, 16 and 24 h post-delivery of lipoplexes.
Events that typically take place 8 h after delivery of complexes to the cells include a high rate of endosomal escape
[31, 33], unpacking of plasmid DNA (pDNA) from vector
[31, 32], some nuclear localization of complexes or pDNA
[31, 33–36], very small amounts of nuclear internalization
of complexes or pDNA [34, 36, 37] and very little production of transgenic protein [34, 38]. Events that typically
take place 16 h after delivery of complexes to the cells
include high rate of nuclear localization of complexes or
pDNA [34, 36], continued nuclear internalization of complexes or pDNA [21, 34, 36, 37] and continued production of transgenic proteins [34,38]. Events that take place
24 h after delivery of complexes to the cells include the
continued nuclear internalization of pDNA [34,36,37,40],
the highest synthesis of transgenic proteins [34, 38, 40]
and mitosis (including distribution of transgenic proteins
and pDNA to daughter cells) [36, 39]. Therefore, the time
points chosen for the investigations in the present study
were selected to capture several key cellular events that
occur throughout the gene delivery process. We also ascertained the potential role of several of the identified
genes for their ability to affect transfection by use of pharmacologic activators or inhibitors of the target endogenous gene. The endogenous genes and pathways that facilitate transfection as identified in the present study can
be used as targets for increasing transfection through cell
priming or for improved DNA carrier design.

Materials and methods
Cell culture and plasmid preparation
HEK 293T cells (ATCC, Manassas, VA, USA) were cultured in
T-75 flasks in Dulbecco’s modified Eagle’s medium containing 4.5 g/l glucose, supplemented with 10% fetal bovine
serum, 1mM sodium pyruvate, 100 units/ml of penicillinstreptomycin (all Gibco, Carlsbad, CA, USA) and maintained
at 37°C in a humidified 5% CO2 atmosphere. For seeding,
cells were dissociated at confluence with 1mM ethylenediaminetetraacetic acid (EDTA) and viable cells were counted
using a hemocytometer and trypan blue dye exclusion assay. Plasmid pEGFP-LUC encodes both the enhanced green
fluorescent protein (EGFP) and firefly luciferase protein
(LUC) under the direction of a cytomegalovirus promoter
(Clontech, Mountain View, CA, USA), and was used for
transfection experiments (see below). Plasmid was purified

from bacteria culture using Qiagen (Valencia, CA, USA) reagents and stored in Tris–EDTA buffer solution (10mM Tris,
1mM EDTA, pH 7.4) at –20°C.
Transfection and sample isolation for microarray
Cells were seeded at a density of 44.8×103 cells/cm2 into
multiple T-75 flasks. After adherence (approximately 18
h after seeding), lipoplexes were formed using LF2000 in
accordance with the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). Briefly, LF2000 transfection reagent diluted in serum-free Opti-MEM media (Invitrogen)
was added dropwise to DNA diluted in Opti-MEM at a lipid:
DNA ratio of 1.5:1, mixed by gentle pipetting, and incubated at room temperature for 20 min. After forming the
lipoplexes, they were delivered to the media above the cells
to deliver 0.15 μg/cm2 of DNA. Those transfection conditions were optimal for high transfection (typically 70–90%)
and low cytotoxicity with optimization performed as described previously [45]. The complexes remained in contact with the cells for the duration of each experiment:
2, 8, 16 and 24h. After the incubation period of the lipoplexes at each time point, cells were dissociated using
0.05% Trypsin-EDTA (except only EDTA for the 2-h condition) and suspended in 1X phosphate-buffered saline
(PBS) at 2–5 million cells/ml and placed on ice. For the 2-h
time point, because very little GFP had been produced,
untreated samples were obtained identically, as were the
treated samples, except no lipoplexes were delivered to
the cells. For the 8-, 16- and 24-h time points, after dissociation, the treated cells were separated into transfected
(GFP+) and untransfected (GFP–) pure cell populations using fluorescence activated cell sorting (FACS), as described
previously [45]. Briefly, at 8, 16 or 24 h after the addition of
complexes, cells were dissociated, counted, and concentrated in 1X PBS and placed on ice, as described above.
Flow cytometric analysis was performed using a B-D FACSVantage SE three-laser, high speed cell sorter (University
of Nebraska–Lincoln’s Center for Biotechnology Flow Cytometry Core Facility) equipped with a 530/15 nm SE laser. A live gate was set on the GFP+ cell population in forward scatter versus side scatter plot to remove cell debris
or clumped cells from the sort. A minimum of 2×106 cells
for each population (GFP+, GFP–) was collected. Cells were
collected at each time point on three different days providing the following independent samples (n=3 for each
sample): 2 h treated, 2 h untreated, 8 h GFP+, 8 h GFP–, 16
h GFP+, 16 h GFP–, 24h GFP+ and 24 h GFP– (for an overview of the experimental design, see Figure 1). RNA from
each sample was then extracted, purified and hybridized
to microarrays (see below).
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Figure 1. Overview of the experimental design (see Materials and methods). HEK 293T cells were seeded and allowed to become
adherent (approximately 18 h). Then, lipoplexes were formed and delivered to adherent cells and allowed to remain in contact for 2,
8, 16 or 24 h. At the 2-h time point, treated cells were harvested and RNA was extracted and hybridized to microarrays. The treated
profile was compared with cells that underwent the same treatments, except no lipoplexes were delivered. At the 8-, 16- or 24-h time
points, treated cells were FACS separated into GFP positive (GFP+; transfected) and GFP negative (GFP–; untransfected) cell populations and RNA was extracted and hybridized to microarrays. The process was repeated on separate days to achieve n=3 for each
population at each time point.

RNA extraction and microarray hybridization
RNA extraction and quality check was performed as described previously [45]. Briefly, after obtaining each sample (24 in total: three each for 2 h treated, 2 h untreated, 8
h GFP+, 8 h GFP–, 16 h GFP+, 16 h GFP–, 24 GFP+ and 24
h GFP–; see also above and Figure 1), total RNA was TRIzol
extracted and further purified using a Qiagen RNeasy column (Qiagen) to achieve a 260/280 ratio greater than 1.8
on Nanodrop 2000 (Thermo Scientific, West Palm Beach,
FL, USA). After quality assessment using an RNA 6000 Nano
LabChip on an Agilent BioAnalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA), purified RNA was reverse transcribed to cDNA and hybridized to Affymetrix GeneChip
Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa
Clara, CA, USA) overnight at 45°C, in accordance with the

manufacturer’s instructions. After streptavidin-phycoerythrin conjugate staining, expression data were read with the
GeneChip Scanner 3000 7G (Affymetrix) to obtain the expression data of over 47 000 transcripts and variants annotated for all known genes of the human genome. Affymetrix GeneChip Operating Software (GCOS, version 1.3) was
used for washing, scanning and basic data analysis, including calculation of absolute values and normalization of the
data with respect to internal standards.
Microarray and bioinformatics analyses
Each microarray provides 11 independent measures of gene
expression (n=11) for over 47,000 transcripts and variants
annotated for all known genes of the human genome.
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Microarray expression data were background adjusted and
normalized [50] and quality tested using R/Bioconductor with the AffyCoreTools library package, with all arrays
showing good hybridization quality, as described previously [44,45]. The gene expression data has been deposited at the NCBI Gene Expression Omnibus (GEO) accession
GSE59666. Differentially expressed genes between treated
and untreated (2-h time point) or GFP+ and GFP– (8-, 16and 24-h time points) were determined using a nonparametric mean-variance smoothing method developed for
R programming environment [51]. Microarray data for the
24-h time point were collected previously and analyzed using linear models [45] and were downloaded from GEO accession GSE20615. Those microarrays were again analyzed
here, using the nonparametric smoothing method, which
resulted in a larger gene set differentially expressed between GFP+ and GFP– gene expression profiles than has
been previously reported. Those results are included in the
present study, along with the pathways and ontologies enriched to the new gene set (see below). Genes differentially
expressed greater than two-fold and posterior probability
greater than 0.99 were used for the bioinformatics analysis. Enrichr [52], an open source and freely available gene
list enrichment analysis tool, was used to identify enriched
pathways for Kyoto Encyclopedia of Genes and Genomes
(KEGG) [53], WikiPathways (WIKI) [54], BioCarta [55], protein–protein interacting proteins (PPI Hub Proteins) [56],
The Comprehensive Resource of Mammalian Protein Complexes (CORUM) [57], Reactome [58] and Gene Ontology
Process (GO) [59]. Each list of differentially expressed genes
was uploaded to the Enrichr [52] website and pathways or
ontologies enriched greater than a combined score of 5
were reported. The combined score is computed by taking the log of the p-value from the Fisher’s exact test multiplied by the Z-score of the deviation from the expected
rank [52]. Among the differentially expressed genes, the
most promising genes that may affect transfection were
identified. The genes were selected based on high differential expression, putative gene role and potential to play a
role in processes that are known to occur during DNA transfer [21, 31–43], and exploratory gene association network
(EGAN) analysis [60]. EGAN analysis was performed as previously described [44] but, briefly, the tool was used to visualize common occurrences among gene–gene interactions and enriched pathways/ontologies [60] and aided in
selecting genes to study further (see Supporting information, Figure S1). After identifying target genes, the NextBio
[61] Pharmaco Atlas was used to identify pharmacologic
agents known to upregulate or downregulate the target
gene with a score above 70. Those pharmacologic agents
were then used for transfection studies in the presence of
pharmacologic agents (see below).

Transfection in the presence of pharmacologic agents
These experiments were performed as previously described
to alter the expression of endogenous target genes identified from microarray analysis [45]. The studies acted primarily as a screening tool to confirm whether a particular
gene plays an important role in the DNA transfer process.
Briefly, transfection studies were performed in the presence and absence of pharmacologic activators or inhibitors of the target genes (selected as described above). HEK
293T cells were seeded in 48-well plates at 44.8×103 cells/
cm2 and, 18h later, pharmacologic agents were delivered
to the media on the cells to achieve the final desired drug
concentration. The pharmacologic agent was allowed to
incubate for 1 h, and then lipoplexes were formed (as described above) and delivered to the media above the cells
(still containing the pharmacologic agent). The pharmacologic agent and lipoplexes remained in contact with the
cells for the next 24 h and then the cells were lysed and
transfection levels were quantified by measuring the luciferase activity (relative light units) using the Luciferase Assay System (Promega, Madison, WI, USA) and luminometer
(Turner Designs, Sunnyvale, CA, USA), and luciferase activity was normalized to the total protein amount determined
with the BCA protein assay (Pierce, Rockford, IL, USA) and
compared with transfection levels in vehicle-only control
cells. The results were reported as the fold-change to eliminate variability in absolute measures of transfection, respectively, for ALMS1, ITGB1, FCGR3A, DOCK10, PACSIN3
and ZDDHC13 genes; pharmacologic activators included
phenethicillin [62], 1,10-phenanthroline [63], ritonavir [64],
nifenazone [62], hydralazine hydrochloride [62], β-acetylγ-O-hexadecyl-l-α-phosphatidylcholine hydrate (B-AGOPCL) [65]; and pharmacologic inhibitors included quipazine
[62], artemisinine [64,66], gentamicin [64], 8-methoxypsoralen [62], valsartan [64] and nicergoline [62] (all from
Sigma- Aldrich, St Louis, MO, USA). The concentrations of
the pharmacologic agents selected for the present study
were comparable to those tested in the literature showing
gene activity [62, 64–66] but were optimized for high transfection and minimal toxicity (not shown) (see Supporting
information, Figure S2). Statistical analysis was performed
using Prism, version 5 (GraphPad, La Jolla, CA, USA) using
Student’s t-test at a 95% confidence level. Data are reported
as the mean±SEM (n=3).
Results
The GFP transgene was delivered to HEK 293T cells using LF2000 transfection reagent. Then, 2 h after delivery
of the lipoplexes, the initial cell response was determined
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using microarray analysis. Changes in the transcriptome
were identified by comparing gene expression profiles of
cells treated with lipoplexes with cells not treated by lipoplexes (Figure 1). All genes found to be differentially expressed two-fold or greater are listed in the Supporting
information (Table S1). Among the greatest differentially
expressed genes in treated cells compared to untreated
cells were: ALMS1, ITGB1, FCGR3A, DOCK10 and ZDDHC13,
which were downregulated 34.5-, 35.7-, 38.5-, 43.5- and
50.0-fold, respectively (Table 1). Among all genes differentially expressed between treated and untreated cells at
the 2-h time point (see Supporting information, Table S1),
only LIMS1 and ITGB1 were found to be enriched to cellular pathways including cell migration, the inflammatory
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response, cell adhesion and cell junctions (Table 2). Taken
together, treated cells were shown to undergo rapid transcriptional changes in response to treatment with lipoplexes
in a highly downregulated manner.
Because most cells internalize lipoplexes within the first
few hours of exposure [21,31,33,34,41–43; Sarah A. Plautz
(S.A.P) unpublished results] but not all cells actually express
the transgene, we next set out to identify those endogenous genes that may facilitate transfection. To do so, lipoplexes were delivered to the cells and, after 8, 16 or 24
h, the treated cell population was sorted into transfected
GFP+ and GFP– subpopulations (Figure 1). Using microarray analysis, changes in the transcriptome were identified
by comparing GFP+ and GFP– endogenous gene expression

Table 1. Differentially expressed genes comparing treated with untreated gene expression profiles after 2 h of exposure to lipoplexes
Gene

Fold Δ

ALMS1
–34.5
ZDHHC13
–35.7
ITGAL
–37.0
		
AI912723
–38.5
CCDC30
–38.5
FCGR3A
–38.5
SLC24A2
–41.7
		
CLLU1
–41.7
ANXA6
–41.7
ITGB1
–43.5
		
PER1
–43.5
TPTE
–45.5
RRM1
–50.0
DOCK10
–50.0
BC040304
–55.6
SLC3A1
–62.5
		
BCL2L10
–83.3

Name
Alstrom syndrome 1
Zinc finger, DHHC-type containing 13
Integrin, alpha L [antigen CD11A (p180), lymphocyte
function-associated antigen 1; alpha polypeptide]
NA
Coiled-coil domain containing 30
Fc fragment of IgG, low affinity IIIa, receptor (CD16a)
Solute carrier family 24 (sodium/potassium/calcium exchanger),
member 2
Chronic lymphocytic leukemia up-regulated 1
Annexin A6
Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen
CD29 includes MDF2, MSK12)
Period homolog 1 (Drosophila)
Transmembrane phosphatase with tensin homology
Ribonucleotide reductase M1
Dedicator of cytokinesis 10
NA
Solute carrier family 3 (cystine, dibasic and neutral amino acid transporters,
activator of cystine, dibasic and neutral amino acid transport), member 1
BCL2-like 10 (apoptosis facilitator)

Fold change indicates differential expression of HEK 293T cells transfected with pEGFPLuc/LF2000 microarrays (n=3) compared to untreated
microarrays (n=3) with a posterior probability greater than 0.99 at the 2-h time point. Negative numbers indicate downregulation.
NA: not available.
Table 2. Enriched pathways for genes differentially expressed between treated and untreated gene expression profiles after 2 h of exposure to
lipoplexes
Source

Term

Score

Genes

KEGG
BioCarta
GO
GO
GO
GO
GO

Leukocyte transendothelial migration (HSA04670)
Local acute inflammatory response (LAIR)
Leukocyte adhesion (GO: 0007159)
Integrin complex (GO: 0008305)
Focal adhesion (GO: 0005925)
Cell-substrate junction (GO: 0030055)
Adherens junction (GO: 0005912)

5.21
11.84
7.14
8.26
7.08
6.69
5.60

LIMS1, ITGB1
LIMS1, ITGB1
LIMS1, ITGB1
LIMS1, ITGB1
LIMS1, ITGB1
LIMS1, ITGB1
LIMS1, ITGB1

Genes found in Table 1 and the Supporting information (Table S1) were found to be over-represented to specific terms. The first column indicates
the source of pathway database; the second column lists the enriched term; the third column lists the enrichment score; and the last column
indicates which of the differentially expressed genes belong to the enriched term. Downregulated genes are shown in italic, and genes greater
than five-fold differentially expressed are shown in bold. For a description of the source or score, see Materials and methods.
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profiles. All genes found to be differentially expressed twofold or greater are listed in the Supporting information (Table S1). At the 8-h time point, the greatest differentially
expressed genes were RAP1A and PACSIN3, both upregulated 38.62- or 6.64-fold, respectively (Table 3). At the 16-h
time point, the greatest differentially expressed genes were
RAP1A and HSPA6, upregulated 17.30- or 7.42-fold, respectively (Table 3). At the 24-h time point, the greatest differentially expressed genes were once again RAP1A and HSPA6,
upregulated 10.28- or 11.35-fold, respectively (Table 3).
We were next interested in understanding how the gene
expression profile changes over time, in terms of the number of genes expressed, as well as which genes were found
to be differentially expressed over multiple time points. The
number of genes differentially expressed (between GFP+
and GFP–) increased from 8 h to 16 h from seven genes to
27 genes, respectively (Figure 2). ARMC8, ATF3 and RAP1A
genes were commonly expressed between the two time
points (Figure 2). The number of genes differentially expressed decreased from 16 h to 24 h from 27 genes to
two genes (Figure 2), respectively, with HSPA6 and RAP1A
genes commonly being expressed between the two time
points (Figure 2). RAP1A showed sustained upregulation in
the transfected cell population compared to untransfected
cell population at the 8-, 16- and 24-h time points (Figure
2; see also Supporting information, Table S1). The largest
number of genes differentially expressed occurred 16 h after exposure to lipoplexes in the transfected cell population.
To determine the role of all differentially expressed genes
in transfected cells at each time point (8, 16 and 24 h; see
Supporting information, Table S1), we performed a pathway
and ontology enrichment analysis (Table 4; see Materials
and methods). Pathways enriched from genes differentially
expressed at the 8-h time point were the mesenchymal–epithelial transition (MET) and integrin pathways, protein complexes (CLTH, HSPA1A and SMARCA4) and GO processes involved in metabolism, proteolysis and catabolism (Table 4).
Pathways enriched at the 16-h time point were spindle and
cell cycle pathways, as well as protein complexes involved

Figure 2. The overlap of genes differentially expressed between
the GFP+ and GFP– gene expression profiles is shown for each
time point. Data represent genes greater than two-fold differentially expressed comparing transfected microarrays (GFP+; n=3)
with treated, untransfected microarrays (GFP–; n=3) with a posterior probability >0.99. The level of differential expression for
each gene is provided in the Supporting information (Table S1).

in cell adhesion (RIAM-Rap1-GTP complex), proliferation
(CDC2-PCNA-CCNB1-GADD45A complex) and stimuli response (MAPK9) (Table 4). Pathways enriched at the 24-h
time point were focal adhesion, migration, MET, integrin
and stimuli response (mitogen-activated protein kinase, IL3, type I interferon, unfolded protein response) pathways,
along with protein complexes involved in paracrine signaling (HGFR), GTPase activity, transport (GABARAPL2) and
cell adhesion (RIAM-Rap1-GTP complex) (Table 4). Taken
together, the pathways and ontologies enriched at each
time point may play a role in transfection, and those genes
differentially expressed greater than five-fold at each time
point may play a significant role in those processes because

Table 3. Temporal cell response after treatment with lipoplexes comparing GFP+ to GFP– gene expression profiles
Time

Gene

Fold

Posterior probability

Accession number

8h

RAP1A
PACSIN3
RAP1A
HSPA6
RAP1A
HSPA6

38.62
6.64
17.30
7.42
10.28
11.35

1.00
1.00
1.00
1.00
1.00
1.00

AB051846
AK000847
AB051846
NM_002155
AB051846
NM_002155

16 h
24 h

Name
RAP1A, member of RAS oncogene family
Protein kinase C and casein kinase substrate in neurons 3
RAP1A, member of RAS oncogene family
Heat shock 70-kDa protein 6 (HSP70B’)
RAP1A, member of RAS oncogene family
Heat shock 70-kDa protein 6 (HSP70B’)

Comparison of GFP+ to GFP– gene expression levels. Differential expression greater than or less than 1 represents upregulation or downregulation,
respectively. Data represent genes differentially expressed comparing transfected microarrays (n=3) with treated, untransfected microarrays (n=3)
with a posterior probability greater than 0.99 and differential expression greater than five-fold. The Supporting information (Table S1) lists all genes
differentially expressed greater than two-fold.
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Table 4. Enriched pathways for genes differentially expressed between GFP+ and GFP– gene expression profiles
Source

Term

Score

Genes

8h
BioCarta
BioCarta
PPI HUB
PPI HUB
CORUM
GO
GO
GO

Mesenchymal-epithelial transition factor (MET) pathway
5.53
Integrin pathway
5.43
HSPA1A
14.27
SMARCA4
6.80
CLTH (PICALM; phosphatidylinositol binding clathrin assembly protein) complex 8.40
Mitochondrial electron transport, NADH to ubiquinone (GO: 0006120)
8.08
Regulation of proteolysis (GO: 0030162)
7.74
Regulation of protein catabolic process (GO: 0042176)
7.54

RAP1A
RAP1A
DNAJB11, PACSIN3, RAP1A
ATF3, RAP1A
ARMC8
NDUFA10
PACSIN3
PACSIN3

16 h
PPI HUB
CORUM
CORUM
CORUM
CORUM
GO

MAPK9
CDC2-PCNA-CCNB1-GADD45A complex
RC complex during G2/M-phase of cell cycle
Cell cycle kinase complex CDC2
RIAM-Rap1-GTP complex
Spindle (GO: 0005819)

5.72
8.06
7.48
7.97
6.47
5.03

TOB1, RAP1A, HSPA6
CCNB1
CCNB1
CCNB1
RAP1A
AURKA

24 h
KEGG
KEGG
KEGG
WIKI
WIKI
WIKI
BioCarta
BioCarta
PPI HUB
CORUM
GO
GO
GO
GO
GO

Focal adhesion (HSA04510)
Leukocyte transendothelial migration (HSA04670)
MAPK signaling pathway (HSA04010)
Hepatocyte growth factor receptor signaling (WP313)
IL-3 signaling pathway (WP286)
Interferon type I (WP585)
MET pathway
Integrin pathway
GABARAPL2
RIAM-Rap1-GTP complex (human)
Response to protein stimulus (GO: 0051789)
Response to unfolded protein (GO: 0006986)
Response to biotic stimulus (GO: 0009607)
Response to chemical stimulus (GO: 0042221)
GTPase activity (GO: 0003924)

5.57
5.36
6.21
5.38
5.36
5.36
5.53
5.43
6.07
9.17
8.85
8.73
7.20
5.11
5.50

RAP1A
RAP1A
RAP1A
RAP1A
RAP1A
RAP1A
RAP1A
RAP1A
HSPA6, RAP1A
RAP1A
HSPA6
HSPA6
HSPA6
HSPA6
RAP1A

Selected enriched terms are listed for differentially expressed transcripts comparing GFP+ microarrays to GFP– microarrays at each indicated time
point after delivery of pEGFPLuc/LF2000 complexes to HEK 293T cells. The first column indicates the name of pathway database; the second
column lists the enriched term; the third column lists the enrichment score; and the last column indicates which of the differentially expressed
genes belong to the enriched term. Downregulated genes are shown in italic, upregulated genes are underlined, and genes greater than five-fold
differentially expressed are shown in bold. For a description of the source or score, see Materials and methods.

they are highly upregulated: 8 h (PACSIN3 and RAP1A), 16 h
(RAP1A and HSPA6) and 24 h (RAP1A and HSPA6) (Table 4).
As reported in the present study, microarray analysis revealed genes highly differentially expressed in treated cells
compared to untreated cells at the 2-h time point and in
GFP+ cells compared to GFP– cells at the 8-, 16- and 24-h
time points (Tables 1 and 3). To discriminate whether any
of the genes identified in the present study have a potential role in transfection as opposed to genes expressed as
a treatment effect, pharmacologic studies were conducted.
Those genes highly differentially expressed at the 2-, 8-,
16- or 24-h time points (Tables 1 and 3) were narrowed to
a smaller subset to further test based on literature review
of each gene’s putative function, potential role in the DNA
transfer process and exploratory gene association network
analysis [60] (see Supporting information, Figure S1; Materials and methods). Highly differentially expressed genes
RAP1A and HSPA6 (Table 3) were not studied using pharmacologic agents because we have previously shown that

perturbing those genes prior to lipoplex delivery can enhance transfection by up to 2.5-fold [45]. The list of genes
was narrowed to ALMS1, ITGB1, FCGR3A, DOCK10, PACSIN3
and ZDDHC13. Pharmacologic agents known to activate or
inhibit each gene were found using NextBio [61] and from
previous studies in the literature [62–66], and were used as
a screening tool to confirm whether a particular gene may
play an important role in the DNA transfer process. The effect of the pharmacologic agent on transfection levels are
summarized in Table 5, with transfection levels provided in
Figure 3. In all pharmacologic studies reported here, no cytotoxicity was observed (see Supporting information, Figure
S2) with the exception of artemisinin (1mM) and nifenazone
(5mM), where minor toxicity was observed (see Supporting
information, Figure S2).
When the ALMS1 gene was activated (phenethicillin) or
inhibited (quipazine), prior to delivery of lipoplexes, transfection levels were reduced by 7.6-fold or increased by 1.3fold, respectively (Figure 3 and Table 5). Similarly, when the
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Table 5. Transfection in the presence of pharmacologic agents
			
Gene
Putative gene function
Pharmacologic agenta

Vehicle
(Control +)

Transfection
fold changeb

ALMS1

Involved in centriole formation and stability [85]
and ciliogenesis [87]

Phenethicillin 10mM ↑ [62]
Quipazine 1 μM ↓ [62]

ddH2O
ddH2O

–76***
1.3*

ITGB1

Ubiquitously expressed adhesion antigen [100],
which regulates immune cell chemotaxis [101]
and inflammatory response after infection [102].
Activation mediates proliferation and inhibits
apoptosis [103]

1, 10-Phen 10 μM ↑ [63]
Artemisinine 1mM ↓ [64,66]

DMSO
CHCl3

1.3*
–58***

FCGR3A

FCGR3A transduces signals to cytoplasm, which
regulate actin, myosin, membrane fusion and
production of reactive oxygen intermediates during
phagocytosis of IgG-opsonized particles [93]

Ritonavir 10 μM ↑ [64]
Gentamicin 10mM ↓ [64]

DMSO
ddH2O

1.3**
–25

DOCK10

Contains a guanine nucleotide exchange factor
domain that activates Rho GTPases with growth
promoting and anti-apoptotic function; promotes
actin cytoskeleton reorganization [97] and motility
via lamellipodia protrusions [98]

Nifenazone 10 μM ↑ [62]
8-methoxy 1 μM ↓ [62]

DMSO
ddH2O

1.3*
–1.4**

PACSIN3

Involved in proteolytic shedding of ectodomain
receptors [115] in dynamin-mediated endocytosis [116]
and tubulin nucleation at the centrosome [117]

Hydralazine 1 μM ↑ [62]
Valsartan 100 μM ↓ [64]

ddH2O
DMSO

–13**
1.5***

ZDDHC13

Palmoylates membrane proteins in Golgi apparatus to
regulate membrane-to-membrane trafficking [108] or
influence interaction of membrane proteins within lipid
rafts [109,110], including Ras GTPases such as RAP1 [109]

B-AGO-PCL 10 μM ↑ [65]
Nicergoline 50 μM ↓ [62]

CHCl3
DMSO

–11
–19

a. Effect of pharmacologic agent on gene or protein activity as reported in the literature: ↑, activation; ↓, inhibition.
b. Transfection fold change comparing cells treated with pharmacologic agent with cells treated with vehicle only (Control+) (Figure 3).
Transfection levels were measured 24 h after delivery of complexes to HEK 293T cells. The concentration of the pharmacologic agent was selected
forminimal cytotoxicity and maximal effect (see Supporting information, Figure S2). 1,10-Phen, 1,10-Phenanthroline; 8-methoxy, 8-methoxypsoralen;
hydralazine, hydralazine hydrochloride; B-AGO-PCL, β-acetyl-γ-O-hexadecyl-l-α-phosphatidylcholine hydrate; ddH2O, double distilled water;
DMSO, dimethyl sulfoxide; CHCl3, chloroform. Data are reported as the mean (n=3) and significant changes between treated and vehicle-only
transfection levels are indicated as: * p<0.05 ; ** p<0.01 ; or *** p<0.001.

ITGB1 gene was activated (1,10-phenanthroline) or inhibited (artemisinine), transfection levels were increased by
1.3-fold or reduced by 5.8-fold, respectively (Figure 3 and
Table 5).When the FCGR3A gene was activated (ritonavir)
or inhibited (gentamicin), transfection levels were increased
by 1.3-fold or decreased by 2.5-fold, respectively (Figure 3
and Table 5). When the DOCK10 gene was activated (nifenazone) or inhibited (8-methoxypsoralen) transfection levels were increased by 1.3-fold or decreased by 1.4-fold, respectively (Figure 3 and Table 5). When the PACSIN3 gene
was activated (hydralazine) or inhibited (valsartan), transfection levels were decreased by 1.3-fold or increased by
1.5-fold, respectively (Figure 3 and Table 5). When the ZDDHC13 gene was activated (β-acetyl-γ-O-hexadecyl-l-αphosphatidylcholine hydrate) or inhibited (nicergoline),
transfection levels were decreased by 1.1-fold or decreased
by 1.9-fold, respectively (Figure 3 and Table 5). Taken together, altering ALMS1, ITGB1, FCGR3A, DOCK10, PACSIN3
or ZDDHC13 gene activity can affect transfection, showing
that microarray analysis can identify genes possibly playing a role in transfection.
The effect of the concentration of the pharmacologic
agents on transfection used to activate ALMS1 or inhibit
ITGB1 or FCGR3A was evaluated next (Figure 3) because

those agents had the largest impact on transfection. For
phenethecillin (ALMS1 activation), the effect of reduced
transfection from the pharmacologic treatment became
less apparent as the concentration of the drug decreased:
at 10 mM, 100 μM and 1 μM, transfection was reduced
by 7.60±0.01-, 1.37±0.14- and 1.17±0.02-fold, respectively
(Figure 4). For artemisinine (ITGB1 inhibition), the effect of
reduced transfection from the pharmacologic treatment
also became less apparent as the concentration of the drug
decreased: at 1 mM, 500 μM, 100 μM and 1 μM, transfection was reduced by 5.78±0.01-, 2.72±0.11-, 1.72±0.04- and
1.19±0.04-fold, respectively (Figure 4). For gentamicin (FCGR3A inhibition), the effect of reduced transfection from
the pharmacologic treatment became less apparent as the
concentration of the drug decreased: at 10mM, 1mM and
10 μM, transfection was reduced by 2.49±0.04-, 1.18±0.12and 1.15±0.09-fold, respectively (Figure 4).
Discussion
Understanding the intracellular molecules and pathways
that may facilitate DNA transfer provides insight into the
potential mechanisms required for efficient transfection

Temporal endogenous gene expression profiles in response to transfection

23

Figure 3. Effect of target gene on transfection for HEK 293T cells treated with indicated pharmacologic agent (black bars) or treated
only with vehicle used to deliver the pharmacologic agent (Control+; open bars) (Table 3) to activate (underlined text) or inhibit
(plain text) indicated genes. After a 1-h incubation period, lipoplexes were delivered and transfection levels were assayed after 24 h
(see Materials and methods). Data are reported as the mean±SEM (n=3) and significant changes between treated and vehicle-only
transfection levels are indicated as: * p<0.05 ; ** p<0.01 ; or *** p<0.001.

[67], offering targets for designing enhanced nonviral gene
delivery systems. Gene transfer requires molecular mediators to actively transfer the delivered DNA [33] through

intracellular barriers, into the nucleus [31, 68–76] and for
transgene expression [77]. Although the routing kinetics of
the lipoplex have been observed as they occur over time
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Figure 4. Effect of concentration of pharmacologic on transfection of HEK 293T cells treated with the indicated pharmacologic agent
(black bars) or treated only with vehicle used to deliver the pharmacologic agent (Control+; open bars) at a range of concentrations.
After a 1-h incubation period, lipoplexes were delivered and transfection levels were assayed after 24 h (see Materials and methods). Data are reported as the mean±SEM (n=3) and significant changes between treated and control+ transfection levels are indicated as: * p<0.05 or *** p<0.001.

and enable the development of transfection models [34,
40, 46, 78, 79], the molecular mediators used by the cell to
route the DNA complex are poorly understood. In the present study, we attempted to fill that gap in knowledge using
a transcriptomics approach aimed at identifying molecules
and pathways involved in key cellular events known to influence transfection at 2, 8, 16 and 24 h after lipoplex delivery. Because mRNA metabolism and catabolism can be
condition- and cell-specific and the mRNA half-life widely
varies from approximately 10 min to 10 h or more, our approach may miss the identification of molecules involved in
short-lived signaling pathways. To address this challenge of
using microarrays and a few selected time points, we integrated the identified endogenous genes and pathways from
the present study with other studies that identified shortlived signaling events into a proposed preliminary model of
the biology of transfection of HEK 293 T cells by lipoplexes
(Figure 5). The endogenous genes and pathways are discussed below in the context of the cellular processes and
timing of those processes that occur during DNA transfer.
Treatment of cells with lipoplexes results in a cellular
downregulation of transcription
In the present study, gene expression profiles were obtained
for HEK 293T cells that were treated with lipoplexes for 2
h compared to untreated cells. Our results show a marked
downregulation of 44 genes compared to untreated cells
(Table 1; see also the Supporting information, Table S1) affecting cellular pathways in junction, adhesion, migration
and inflammation (Figure 5 and Table 2). During this period, the treated cells have been reported to internalize lipoplexes into endosomes and lipoplexes attempt to escape the endosome [22, 34, 40] at the same time as the
cell is actively coping with the cytotoxic stress induced by

lipoplexes or foreign DNA [80] (Figure 5). Various strategies have been devised to reduce the cytotoxicity, such as
maturation time for forming lipoplexes, DNA to liposome
ratio, size of lipoplexes and serum-free cell culture conditions [80,81]. However, one recent study advocates a molecular method to reduce cytotoxicity, based on knowing what
gene is involved in the toxicity [7] and we advocate the use
of a molecular basis to guide the design of improved DNA
delivery systems with enhanced transfection [44, 45]. Because all of the genes identified in the present study at the
2-h time point were highly downregulated, the cellular response to exposure of lipoplexes is suggestive of a type of
cellular shutdown of transcription, presumably to prevent
further cytotoxic assault [22] and further uptake of foreign
DNA [80]. We also noted that total RNA was reduced in
cells treated with lipoplexes compared to untreated samples
(data not shown), providing further evidence for a transcriptional shutdown. The transcriptional shutdown in response
to short-term stress is reported to occur in other eukaryotic systems that act to rapidly destabilize mRNAs and coordinate mRNA turnover within a few minutes to achieve a
strong activity of stress genes [82]. In the present study, we
identified those genes that may play a role in processes that
occur in HEK 293T cells after a 2-h exposure to lipoplexes;
specifically, ALMS1, ITGB1, DOCK10, FCGR3A and ZDDHC13
genes (Figure 5 and Table 1), which are discussed below in
terms of potential hallmarks of the cell shutdown. However, whether the shutdown event is positive or negative
for transfection is unclear given the effects of pharmacologic activation of target genes, as discussed below (Table 5
and Figure 3). The results from our studies demonstrate that
there are many genes responsible for DNA transfer at different time points and that activating or inhibiting a single
gene is unlikely to have a prodigious effect on DNA transfer, agreeing with our pharmacologic studies.
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Figure 5. Proposed interaction of genes and pathways during pDNA transfer as identified in the present study. Shown is the outline
of a HEK 293T cell with a partial outline of a daughter cell shown in the upper right. The DNA transfer process is shown within the
cell, with the initial event of the complex binding to the cell occurring at the far left at time 0 h and subsequent events (large red arrows) occurring over time, from left-to-right. The time points chosen for microarray analysis in the present study are indicated with
a green arrow at the bottom and correspond to molecular events shown above the arrow within the cell. Genes, enriched pathways
and molecular intermediates as identified or discussed in the present study at each time point appear in the context of the DNA
transfer process. Multiple molecular intermediates remain unlisted.

During the first few hours after lipoplex treatment, filopodia have been reported to play a pivotal role in cellular binding and processing of lipoplexes and polyplexes
prior to cellular entry via endocytosis [83,84]. Filopodia are
slender, actin-rich protrusions that extend outward from
the cell body to sense the extracellular environment. Three
genes identified in the present study (ALMS1, FCGR3A and
DOCK10) are implicated in the generation of such podia
protrusions (Figure 5). ALMS1 is ubiquitously expressed and
involved in centriole formation and stability [85], the cell cycle [86] and ciliogenesis [87], and contains two nuclear localization sequences [88], which are all cellular processes
or molecules that play a role in transfection [37, 39, 83].
Because the cellular response at 2 h was to downregulate
the ALMS1 gene (Table 1), the cell may be acting in defense
as a result of exposure to foreign DNA by preventing the
further uptake of lipoplexes via cilia. Hence, we hypothesized that activating ALMS1 with phenethicillin (penicillin
analog) [62] prior to the delivery of lipoplexes would enhance cilia-mediated endocytosis [83, 87] and cell cycle processes [39,86] leading to enhanced transfection. Similarly,

we hypothesized that inhibiting ALSM1 with quipazine (serotonin reuptake inhibitor) [62] prior to lipoplex delivery
would lead to decreased transfection. By contrast to our
hypothesis, activating ALMS1 lead to a drastic reduction in
transfection (7.6-fold) (Table 5) in a dose-dependent manner (Figure 4), at the same time as inhibiting ALMS1 slightly
increased transfection (1.3-fold) (Table 5). The conflicting result to our hypothesis highlights: (i) that nonspecific pharmacologic agents for ALMS1 may not be able to adequately
test our hypothesis; (ii) that there is a potentially larger role
of ALMS1 beyond transfection because cilia and basal bodies are involved in many inter- and intracellular processes
[89,90]; or (iii) that cilia-mediated endocytosis results in an
intracellular fate of the lipoplex leading to altered degradation of the lipoplex [91]. In any event, altering ALMS1 levels
may drastically impact transfection.
FCGR3A, also implicated in the generation of podia [92]
that have been shown to facilitate endocytosis of lipoplexes
[83], was identified as highly downregulated (Table 1) 2 h
after exposure of HEK 293T cells to lipoplexes. FCGR3A receptors act to transduce signals to the cytoplasm, which
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regulate actin, myosin, membrane fusion and the production of reactive oxygen intermediates during phagocytosis
of immunoglobulin (Ig)G-opsonized particles [93] by leukocytes [94]. Although HEK 293T is not a leukocyte cell line,
the FCGR3A receptor can also be found on embryonic epithelial cells [94] and maintain the necessary cellular machinery for endocytosis without exhibiting respiratory burst [95].
Activation of the receptor can lead to increased proliferation [94] and has been reported to enhance viral infection
[96]. Hence, because of those studies and the impact of podia and endocytosis on transfection [83], we hypothesized
that activation of FCGR3A with the antiretroviral ritonavir
[64] would lead to increased endocytosis of lipoplexes and
therefore increase transfection. Similarly, we hypothesized
that inhibition of FCGR3A by gentamicin (aminoglycoside
antibiotic) [64] prior to delivery of lipoplexes would lead to
reduced transfection. In support of our hypotheses, activating FCGR3A increased transfection slightly (1.3-fold) (Table 5) at the same time as inhibiting FCGR3A drastically reduced transfection (2.5-fold) (Table 5) in a dose-dependent
manner (Figure 4). The distribution of FCGR3A receptor in
HEK 293T cells should be verified, and the exact mechanisms of FCGR3A in transfection of HEK 293T cells remain
unclear. However, the results advocate a role of FCGR3A in
lipoplex-mediated transfection.
DOCK10, also implicated in the generation of podia that
have been shown to facilitate endocytosis of lipoplexes
[83],was identified as being highly downregulated (Table 1)
2 h after exposure of HEK 293T cells to lipoplexes. DOCK10
contains a guanine nucleotide exchange factor domain,
which activates GTPases (such as RAP1A as discussed below) with anti-apoptotic function, promotes actin cytoskeleton reorganization and proliferation [97], and enhances
motility via lamellipodia protrusions [98]. Because DOCK10
function agrees with observations correlated with transfection, such as endocytosis of lipoplexes via podia [83], DNA
repair and activation of protein folding chaperones [44,45],
cell cycle [39], and cytoskeletal signaling [99], we hypothesized that activation (by nifenazone, a nonsteroidal anti-inflammatory agent) [62] or inhibition (8-methoxypsoralen, a
selective inhibitor of DNA synthesis) [62] of DOCK10 prior
to delivery of lipoplexes would lead to enhanced or decreased transfection, respectively. The results reported in
the present study support our hypotheses, with activation
or inhibition of DOCK10 enhancing or reducing transfection by 1.3- or 1.4-fold, respectively (Table 5).
Another gene significantly downregulated in cells after
2 h of exposure to lipoplexes was ITGB1 (Table 1), a ubiquitously expressed adhesion antigen [100], which regulates
immune cell chemotaxis [101] and the inflammatory response after infection [102] (Figure 5). Because the activation of ITGB1 mediates proliferation and inhibits apoptosis [103] and increased cell proliferation is associated with

increased transfection [39],we hypothesized that activation (1,10-phenanthroline, uncouples oxidation from phosphorylation in metabolic cycle) [63] or inhibition (artemisinine, an antimalarial drug) [64, 66] of ITGB1 would increase
or decrease transfection, respectively. Indeed, activating
ITGB1 prior to delivery of lipoplexes resulted in a 1.3-fold
increased transfection (Table 5), which could be a result of
its known effect on proliferative capacity of the cells and
therefore increased transfection [39]. Similarly, inhibiting
ITGB1 prior to delivery of lipoplexes resulted in drastically
reduced transfection (5.8-fold) (Table 5) in a concentrationdependent manner (Figure 4), which could be a result of
the reduced capacity of ITBG1 to prevent necrosis [102]
and toxicity induced by the lipoplex [80], which has been
shown to inhibit transgene expression [104]. The ability of
ITGB1 to drastically alter transfection provides evidence that
ITGB1 may be involved in lipoplex-mediated gene delivery and agrees with one study suggesting that lipoplexes
electrostatically interact with negative regions of activated
β-integrins [105] to piggyback internalization along with the
activated integrins. It was advocated that adhesion receptors, in general, serve as natural cell surface receptors for
lipoplexes [105] along with other groups showing intercellular cell-adhesion molecule-1, syndecans [106] and integrins [106] to enhance nonviral transfection [107]. Additionally, we advocate a role for integrins in transfection because
activating RAP1A, involved in integrin-mediated cell adhesion, increases transfection [44,45] (with a role in transfection as discussed below).
ZDDHC13 was identified as another gene significantly
downregulated in cells after 2 h of exposure to lipoplexes
(Figure 5 and Table 1); ZDDHC13 serves to palmitoylate
membrane proteins in the Golgi apparatus and regulate
membrane-to-membrane trafficking [108] or influence
the interaction of membrane proteins within lipid rafts
[109,110], including Ras GTPases such as RAP1A [109]. Because lipid rafts are associated with sites of endocytosis for
lipoplexes [111, 112], we hypothesized that activation (BAGO-PCL, an inflammatory inducer and activator of MAP
kinase and MAP kinase kinase) [65] or inhibition (nicergoline, α-adrenergic receptor antagonist and vasodilator) [62]
of ZDDHC13 would lead to increased or decreased transfection, respectively. Activating ZDDHC13 resulted in a slight
1.1-fold decrease in transfection (Table 5) and did not support our hypothesis, suggesting that activation of ZDDHC13
may not be directly involved in transfection or that B-AGOPCL is not suitable for testing our hypothesis. However, inhibiting ZDDHC13 resulted in a 1.9-fold decrease in transfection (Table 5), which supports our hypothesis suggesting
that disrupting the ability of the cell to enrich proteins to
lipid rafts would probably lead to reduced endocytosis of
lipoplexes and therefore reduced transfection. Increasing
the concentration of either pharmacologic agent resulted
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in a cytotoxic effect (data not shown), suggesting that ZDDHC13-mediated palmitoylation plays a larger role than
just membrane trafficking of lipoplexes [113, 114]. The exact mechanism by which transfection is altered by inhibiting ZDDHC13 remains unknown and requires further investigation, although presumably because of the ability of
ZDDHC13 to affect lipid rafts, the intracellular fate of the
lipoplex cargo is also altered, which has been shown to
drastically influence transfection [76, 91]. In summary, the
activity of endogenous genes and pathways involved in filopodia protrusions (ALMS1, FCGR3A and DOCK10), integrin signaling (ITGB1) and membrane trafficking (ZDDHC13)
may affect transfection early in the DNA transfer process
(Figure 5).
Transfected cells overcome cell shutdown and barriers
to transfection
As described above, 2 h after lipoplex delivery, all cells exhibited a ‘shutdown,’ as indicated by the highly downregulated nature of all differentially expressed genes (see Supporting information, Table S1). However, although not all
cells eventually express the transgene, some cells do overcome the transcriptional shutdown event and express the
transgene. Several cellular processes are known to occur
over the course of the next hours (from internalization until transgene expression is detected) (Figure 5), as shown
by trafficking studies in the literature [21, 31–40]. What remains unknown are the molecules and pathways that participate in those processes, thereby preventing the rational design of enhanced nonviral gene delivery systems. By
comparing gene expression profiles for transfected cells
(GFP+) with untransfected cells (GFP–) over a time course
of transfection, we were able to identify potential genes
that may aid in overcoming barriers to transfection. Specifically, we targeted genes that occur in processes during
DNA transfer 8, 16 and 24 h after delivery of lipoplexes, as
described below (Figures 1 and 5).
Cellular processes that occur 8 h after exposure of lipoplexes to cells include endosomal escape [31, 33], followed
by unpacking of plasmid [31, 32], nuclear localization [31,
33–36], nuclear entry [34,36,37] and a small amount of GFP
synthesis [34,38]. By comparing GFP+ and GFP– gene expression profiles, we found PACSIN3 and RAP1A genes to
be upregulated at least five-fold, 8 h after exposure to lipoplexes (Figure 5 and Table 3). PACSIN3 is a gene involved
in proteolytic shedding of ectodomain receptors [115], acting to reduce dynamin-mediated endocytosis [116] and involved in tubulin nucleation at the centrosome [117]. Given
the gene product function, we hypothesized that activation (hydralazine hydrochloride, an inhibitor of membrane-bound enzymes) [62] or inhibition (valsartan, an angiotensin-receptor blocker) [64] of PACSIN3 would lead to
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decreased or increased transfection, respectively. Supporting our hypothesis, activating PACSIN3 resulted in a 1.3fold decrease in transfection presumably as a result of decreased endocytosis, which is the primary uptake route of
lipoplexes into the cell [91]. Similarly, inhibiting PACSIN3 resulted in a 1.5-fold increase in transfection, probably a result of enhanced endocytosis of lipoplexes or stabilization
of the microtubule network, which may enhance transport
of lipoplexes to the cell nucleus [118]. The exact mechanism
by which PACSIN3 affects nonviral transfection remains unclear but, given the processes that occur 8 h after delivery
of lipoplexes and the putative function of PACSIN3, future
studies should be conducted to determine the involvement
of PACSIN3 in endocytosis of lipoplexes, nucleation and
modification of the microtubule network, and potential enhancement in nuclear uptake of pDNA.
RAP1A was also overexpressed in the GFP+ to GFP– gene
profile comparison after 8, 16 and 24 h of exposure of lipoplexes to the cells (Figure 5 and Table 3). The results suggest that RAP1A plays a role in the cellular processes known
to occur at those time points: 8 h (endosomal escape [31,
33], followed by unpacking of plasmid [31, 32], nuclear localization [31, 33–36], nuclear entry [34, 36, 37] and a small
amount of GFP synthesis [34,38]); 16 h (nuclear localization
[34–36], nuclear entry [21, 34, 36, 37] and GFP synthesis
[34,38]); and 24 h (2 mitosis [36, 39], high nuclear plasmid
number [34, 36, 37, 40] and the highest production of transgene [34,38,40]). RAP1A is a small G protein (GTPase) that is
activated by guanine nucleotide exchange factors, growth
factors, cytokines and many other cell-surface receptors to
act as a downstream effector promoting proliferation, cell
survival, vesicular trafficking, cytoskeletal organization, integrin-mediated cell adhesion, increased proliferation, focal adhesions and phagocytosis [119, 120]. In our previous
work, we found RAP1A to be upregulated at the 24-h time
point in GFP+ cells relative to GFP– cells and that activating RAP1A prior to lipoplex delivery increased transfection
two-fold [45], probably affecting cellular processes known
to affect transfection such as cell cycle [39], cell survival
[80, 102, 104] and endocytosis [111, 112]. In the present
study, RAP1A continues to show a potential role in nonviral gene delivery because RAP1A was overexpressed at 8,
16 and 24 h when using the nonlinear method for calculating differential expression [51] (see Materials and methods).
Two potential RAP1A activators (DOCK10 and ZDDHC13;
see above) and three effectors (ALMS1, FCGR3A and ITGB1)
were downregulated 2 h after exposure to lipoplexes. Given
the 38.62-fold upregulation of RAP1A at the 8-h time point
(Table 3), it is possible that the cells able to overcome the
transcriptional shutdown and achieve transfection may be
those cells that do not exhibit a marked downregulation of
DOCK10 or ZDDHC13 at the 2-h time point because activating those genes, as described above, would lead to
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enhanced transfection. During the 16- and 24-h time points,
RAP1A could play a role in vesicular trafficking and cytoskeletal organization [119, 120] because activating RAP1A
acts to acetylate microtubules, which could increase molecular trafficking of lipoplexes to the nucleus, and therefore
lead to increased transfection [108]. Additionally, GTPase
signaling transduction (e.g. DOCK10; see above) via cyclic
adenosine monophosphate and protein kinase A can activate RAP1A, and protein kinase A has been recently shown
to modulate intracellular routing of lipoplexes [121]. Taken
together, a potential relationship among expression levels
of RAP1Aactivators, RAP1A and RAP1A-effectors with cellular processes such as focal adhesion, integrin complex, migration, apoptosis, inflammation and cytoskeletal signaling
may act together to affect DNA transfer (Figure 5).
HSPA6 was also overexpressed in the GFP+ to GFP– gene
profile comparison after 16 and 24 h of exposure of lipoplexes to the cells (Figure 5 and Table 3). The results suggest that HSPA6 plays a role in the cellular processes noted
to occur at those time points [21, 34–40]. HSPA6, heat shock
70-kDa protein 6 (HSP70B’), is primarily stress inducible and
acts to maintain cell viability [122,123], although HSPA6 has
also been shown to facilitate receptor-mediated endocytosis [124], nuclear import of viral particles [125] and podia
resorption [126]. In our previous work using linear models
for differential expression determination, we found HSPA6
to be upregulated at the 24-h time point in GFP+ cells relative to GFP– cells and that activating HSPA6 prior to lipoplex delivery increased transfection by 2.5-fold [45], probably by altering cellular processes that affect transfection
such as nuclear import [125], stabilization of transgene protein folding [122, 123] or podia resorption, which is tied to
the cell cycle [126]. In the present study, HSPA6 continues
to show a potential role in nonviral gene delivery because
HSPA6 was overexpressed at 16h and again at 24 h when
using the nonlinear method for calculating differential expression [51] (see Materials and methods). Taken together,
HSPA6 may also be involved in nonviral transfection by affecting cellular processes such as cell stress/survival, cell
cycle and the response to unfolded protein (Figure 5). In
summary, the genes and pathways identified in the present
study provide a starting foundation for a preliminary model
of the biology of transfection (Figure 5), as well as for future studies to further determine the exact mechanism by
which transfection is enhanced.
Conclusions
Identifying those genes and pathways that aid in overcoming barriers to transfection provides targets for engineering enhanced delivery systems and enabling their therapeutic use. In the present study, we began such an endeavor

using microarrays to give a temporal and high throughput
view of the genes and pathways that occur during DNA
transfer when using lipoplexes, and extend our endeavor to
polyplexes (in our complementary work) [48]. In the present study, treating cells with lipoplexes showed a transcriptional shutdown of genes involved in cell migration, the inflammatory response, adhesion and cell junctions, which
appear to be important to DNA delivery because of their
ability to modulate transfection. Possibly more important
are the genes and pathways utilized by transfected cells
to overcome cellular barriers to transfection. Those genes
identified in the present study are involved in metabolism,
stimuli response, cell adhesion, proliferation and membrane
transport, and are able to modulate transfection. The genes,
pathways and pharmacologic agents identified in the present study to alter transfection provide a basis to further explore mechanisms of DNA transfer, prime cells for enhanced
transfection from existing DNA delivery strategies and engineer novel nonviral systems that can achieve enhanced
transgene expression.
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Figure S1. Exploring the interaction among genes and pathways by adding enriched genes and pathways to a network in EGAN to explore and identify candidate genes for a potential role in transfection for the 2-h time point (A), 8-h time point (B), 16-h time point (C) and 24-h time point (D).
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Suppl. 2

Figure S2. Phase images taken on Leica DMI 3000B (Bannockburn, IL, USA) to assess cell viability and morphology. HEK 293T cells were seeded, allowed to adhere (approximately 18 h); then pharmacologic agent or vehicle control+ was delivered to the media above the cells and after a 1-h incubation, lipoplexes were formed and delivered to the cells. After 24 h, images were taken at ×100 magnification (scale bar is the same for all images
and as shown is 200 μM), with representative images shown. (A) Phenethicillin 10mM, (B) phenethicillin 100 μM, (C) phenethicillin 1 μM, (D) quipazine 1 μM, (E) 1,10-phenanthroline 10 μM, (F) artemisinine 1mM, (G) artemisinine 500 μM, (H) artemisinine 100 μM, (I) artemisinine 1 μM, (J) ritonavir 10 μM, (K) gentamicin 10mM, (L) gentamicin 1mM, (M) gentamicin 10 μM, (N) nifenazone 5mM, (O) 8-methoxypsoralen 10 μM, (P) hydralazine
hydrochloride 100 μM, (Q) valsartan 100 μM, (R) β-acetyl-γ-O-hexadecyl-l-α-phosphatidylcholine hydrate 10 μM, (S) nicergoline 50 μM, (T) ddH2O
vehicle control+, (U) CHCL3 vehicle control+, (V) DMSO vehicle control+ and (W) control–. In some cases, when conducting studies using artemisinin at a 1mM concentration (F), some locations in the well showed precipitation of the pharmacologic agent and minor toxicity to the cells. Minor
toxicity was also observed when conducting studies using nifenazone at a 5mM concentration (N).

Table S1. Genes differentially expressed greater than two-fold at 2, 8, 16 and 24 h after delivery of lipoplexes.
Time
Point

Affy Probe
ID

Gene symbol

Gene name

Accession
number

Posterior
Probability

Differential
Expression1

2h

1558501_at
1555247_a_a
t

DNM3

dynamin 3

AI631915

0.995

0.478

NA

NA

AF394782

0.990

0.477

221765_at

UGCG

AI378044

0.993

0.465

33148_at

ZFR

AI459274

0.993

0.346

242321_at

PTPN14

protein tyrosine phosphatase,
non-receptor type 14

AI628689

0.991

0.346

235742_at

RHOC

ras homolog family member C

AI436197

0.997

0.276

235318_at

FBN1

fibrillin 1

AW955612

0.997

0.111

1555890_at

BC040701

BC040701

0.993

0.110

231905_at

C20orf96

AL034548

0.998

0.076

233957_at

AL117426

NA
chromosome 20 open reading
frame 96
NA

AL117426

1.000

0.075

244303_at

AI809906

NA

AI809906

0.995

0.073

229896_at

GTF2I

general transcription factor IIi

H41907

0.992

0.073

231482_at

AW274257

AW274257

0.998

0.073

230574_at

LOC100130938

AW139393

0.991

0.069

1565628_at

BM849515

NA
uncharacterized
LOC100130938
NA

BM849515

0.992

0.068

1560559_at

AL137539

NA

AL137539

0.993

0.063

214432_at

ATP1A3

ATPase, Na+/K+ transporting,
alpha 3 polypeptide

NM_000703

0.995

0.059

205666_at

FMO1

NM_002021

0.996

0.051

220450_at

NM_024914

NM_024914

0.993

0.044

220550_at

FBXO4

flavin containing
monooxygenase 1
Homo sapiens hypothetical
protein FLJ13262 (FLJ13262),
mRNA
F-box protein 4

NM_018007

0.998

0.042

241279_at

AV649908

NA

AV649908

0.996

0.040

1570259_at

LIMS1

LIM and senescent cell antigenlike domains 1

BC015843

0.994

0.040

1569371_at

LRRC59

BC033695

0.995

0.038

214400_at

INSL3

AI991694

0.990

0.036

217558_at

CYP2C9

cytochrome P450, family 2,
subfamily C, polypeptide 9

BE971373

0.992

0.035

237825_x_at

R51853

possible contaminated source

R51853

0.990

0.032

233788_at

ALMS1

alstrom syndrome 1

AK021679

0.996

0.029

237999_at

AW195867

NA

AW195867

0.996

0.028

ITGAL

integrin, alpha L (antigen
CD11A (p180), lymphocyte
function-associated antigen 1;
alpha polypeptide)

BC008777

0.991

0.027

1554240_a_a
t

UDP-glucose ceramide
glucosyltransferase
zinc finger RNA binding
protein

leucine rich repeat containing
59
insulin-like 3 (Leydig cell)

8h

16 h

240250_at

AI912723

243036_at

CCDC30

204006_s_at

NM_000570

229110_at

SLC24A2

239244_at

AI806127

244250_at

AI912723

0.991

0.026

AW364693

0.999

0.026

NM_000570

0.994

0.026

solute carrier family 24
(sodium/potassium/calcium
exchanger), member 2

N50083

0.991

0.024

NA

AI806127

0.992

0.024

ANXA6

annexin A6

AI917653

0.991

0.024

1561042_at

ITGB1

integrin, beta 1 (fibronectin
receptor, beta polypeptide,
antigen CD29 includes MDF2,
MSK12)

AF086249

0.996

0.023

244677_at

AA416756

NA

AA416756

0.996

0.023

220205_at

TPTE

transmembrane phosphatase
with tensin homology

NM_013315

0.997

0.022

234134_at

AF113689

NA

AF113689

0.996

0.020

219279_at

DOCK10

dedicator of cytokinesis 10

NM_017718

0.996

0.020

244436_at
1556171_a_a
t

BF829112

NA

BF829112

0.997

0.020

BC040304

NA

BC040304

0.996

0.018

NM_000341

0.991

0.016

AI813346

0.990

0.012

Accession
number

Posterior
Probability

Differential
Expression2

AB051846

1.000

38.623

AK000847

1.000

6.641

NM_006860

0.990

3.483

NM_004544

0.993

3.333

BC001144

0.991

3.025

NM_001674

0.999

2.687

205800_at

SLC3A1

236491_at

BCL2L10

Affy Probe
ID
1555340_x_a
t

Gene symbol

NA
coiled-coil domain containing
30
NA

solute carrier family 3 (cystine,
dibasic and neutral amino acid
transporters, activator of
cystine, dibasic and neutral
amino acid transport), member
1
BCL2-like 10 (apoptosis
facilitator)
Gene name

222227_at

PACSIN3

205037_at

IFT27

217860_at

NDUFA10

223054_at

DNAJB11

202672_s_at

ATF3

RAP1A, member of RAS
oncogene family
protein kinase C and casein
kinase substrate in neurons 3
intraflagellar transport 27
homolog (Chlamydomonas)
NADH dehydrogenase
(ubiquinone) 1 alpha
subcomplex, 10, 42kDa
DnaJ (Hsp40) homolog,
subfamily B, member 11
activating transcription factor 3

244528_at

ARMC8

armadillo repeat containing 8

AI684748

0.992

0.351

Affy Probe
ID

Gene symbol

Gene name

Accession
number

Posterior
Probability

Differential
Expression2

1555339_at

RAP1A

AB051846

1.000

17.297

213418_at

HSPA6

NM_002155

1.000

7.417

RAP1A

RAP1A, member of RAS
oncogene family
heat shock 70kDa protein 6
(HSP70B')

1553718_at

ZNF548

NM_152909

0.997

3.074

AF507950

0.998

2.943

ATF3

zinc finger protein 548
long intergenic non-protein
coding RNA 32
activating transcription factor 3

1559291_at

LINC00032

202672_s_at

NM_001674

0.995

2.856

222227_at

AK000847

NA

AK000847

0.999

2.806

214138_at

ZNF79

zinc finger protein 79

AA284829

0.999

2.802

205021_s_at

FOXN3

AA860806

0.993

2.403

1559995_at

SAMD14

BG911806

0.993

2.233

206512_at

NM_005083

forkhead box N3
sterile alpha motif domain
containing 14
NA

NM_005083

0.997

2.135

240789_at

W80619

NA

W80619

0.991

0.493

1555279_at

ARMC8

armadillo repeat containing 8

BC007934

0.990

0.481

217659_at

AA457019

NA

AA457019

0.990

0.460

204092_s_at

AURKA

aurora kinase A

NM_003600

0.996

0.408

228729_at

CCNB1

N90191

0.995

0.408

226021_at

RDH10

AW150720

0.994

0.396

215029_at

AL117451

AL117451

0.994

0.386

219031_s_at

NIP7

NM_016101

0.992

0.380

1569142_at

TRIM13

BC029514

0.992

0.376

232861_at

PDP2

cyclin B1
retinol dehydrogenase 10 (alltrans)
NA
nuclear import 7 homolog (S.
cerevisiae)
tripartite motif containing 13
pyruvate dehyrogenase
phosphatase catalytic subunit 2

AB037769

0.993

0.366

1556410_a_a
t
202704_at

24 h

KRTAP19-1

keratin associated protein 19-1

AJ457067

0.997

0.355

TOB1

transducer of ERBB2, 1

AA675892

0.994

0.349

228273_at

PRR11

BG165011

0.992

0.345

204407_at

TTF2

AF080255

0.990

0.345

206355_at

GNAL

R20102

0.995

0.342

213931_at
1569181_x_a
t

AI819238

proline rich 11
transcription termination factor,
RNA polymerase II
guanine nucleotide binding
protein (G protein), alpha
activating activity polypeptide,
olfactory type
NA

AI819238

0.991

0.338

BC017896

NA

BC017896

0.993

0.329

Gene symbol

Gene name

Accession
number

Posterior
Probability

Differential
Expression2

Affy Probe
ID

RAP1A, member of RAS
AB051846
1.000
10.28
oncogene family
heat shock 70kDa protein 6
213418_at
HSPA6
NM_002155
1.000
11.35
(HSP70B')
1Differential expression represents comparison of microarray gene expression from cells treated with complexes (n = 3) to
microarray gene expression from cells left untreated (n = 3). 2Differential expression represents comparison of microarray gene
expression from cells treated and transfection (GFP+; n = 3) to microarray gene expression from cells treated and untransfected
(GFP-; n = 3. Differential expression greater than or less than 1 represents upregulation or downregulation, respectively.
1555339_at

RAP1A

